These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 30859285)

  • 41. Effectiveness of
    Liu F; Zhang Q; Zhou D; Dong J
    BMC Cancer; 2019 Apr; 19(1):323. PubMed ID: 30953476
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model.
    Dutour A; Decouvelaere AV; Monteil J; Duclos ME; Roualdes O; Rousseau R; Marec-Bérard P
    J Nucl Med; 2009 Sep; 50(9):1533-40. PubMed ID: 19690032
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prediction of chemotherapy response by PET-CT in osteosarcoma: correlation with histologic necrosis.
    Bajpai J; Kumar R; Sreenivas V; Sharma MC; Khan SA; Rastogi S; Malhotra A; Gamnagatti S; Kumar R; Safaya R; Bakhshi S
    J Pediatr Hematol Oncol; 2011 Oct; 33(7):e271-8. PubMed ID: 22193290
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Establishment and validation of a nomogram with intratumoral heterogeneity derived from
    Gu B; Zhang J; Ma G; Song S; Shi L; Zhang Y; Yang Z
    BMC Cancer; 2020 Jan; 20(1):37. PubMed ID: 31941465
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Textural features of
    Cheng L; Zhang J; Wang Y; Xu X; Zhang Y; Zhang Y; Liu G; Cheng J
    Ann Nucl Med; 2017 Aug; 31(7):544-552. PubMed ID: 28646331
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
    Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predicting Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer with Textural Features Derived from Pretreatment
    Beukinga RJ; Hulshoff JB; van Dijk LV; Muijs CT; Burgerhof JGM; Kats-Ugurlu G; Slart RHJA; Slump CH; Mul VEM; Plukker JTM
    J Nucl Med; 2017 May; 58(5):723-729. PubMed ID: 27738011
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The clinical value of texture analysis of dual-time-point
    Nakajo M; Jinguji M; Aoki M; Tani A; Sato M; Yoshiura T
    Eur Radiol; 2020 Mar; 30(3):1759-1769. PubMed ID: 31728684
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical utility of texture analysis of 18F-FDG PET/CT in patients with Stage I lung cancer treated with stereotactic body radiotherapy.
    Takeda K; Takanami K; Shirata Y; Yamamoto T; Takahashi N; Ito K; Takase K; Jingu K
    J Radiat Res; 2017 Nov; 58(6):862-869. PubMed ID: 29036692
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
    Groheux D; Hindié E; Giacchetti S; Hamy AS; Berger F; Merlet P; de Roquancourt A; de Cremoux P; Marty M; Hatt M; Espié M
    Eur J Cancer; 2014 Jul; 50(11):1864-71. PubMed ID: 24841218
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [18F] FDG Positron Emission Tomography (PET) Tumor and Penumbra Imaging Features Predict Recurrence in Non-Small Cell Lung Cancer.
    Mattonen SA; Davidzon GA; Bakr S; Echegaray S; Leung ANC; Vasanawala M; Horng G; Napel S; Nair VS
    Tomography; 2019 Mar; 5(1):145-153. PubMed ID: 30854452
    [TBL] [Abstract][Full Text] [Related]  

  • 52.
    Nakajo M; Jinguji M; Shinaji T; Tani A; Nakabeppu Y; Nakajo M; Nakajo A; Natsugoe S; Yoshiura T
    Br J Radiol; 2019 Feb; 92(1094):20180620. PubMed ID: 30273012
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy.
    Pyka T; Bundschuh RA; Andratschke N; Mayer B; Specht HM; Papp L; Zsótér N; Essler M
    Radiat Oncol; 2015 Apr; 10():100. PubMed ID: 25900186
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumor heterogeneity measured on F-18 fluorodeoxyglucose positron emission tomography/computed tomography combined with plasma Epstein-Barr Virus load predicts prognosis in patients with primary nasopharyngeal carcinoma.
    Chan SC; Chang KP; Fang YD; Tsang NM; Ng SH; Hsu CL; Liao CT; Yen TC
    Laryngoscope; 2017 Jan; 127(1):E22-E28. PubMed ID: 27435352
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differentiating the grades of thymic epithelial tumor malignancy using textural features of intratumoral heterogeneity via (18)F-FDG PET/CT.
    Lee HS; Oh JS; Park YS; Jang SJ; Choi IS; Ryu JS
    Ann Nucl Med; 2016 May; 30(4):309-19. PubMed ID: 26868139
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early Assessment of Response to Neoadjuvant Chemotherapy with 18F-FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer.
    Chung YS; Kim HS; Lee JY; Kang WJ; Nam EJ; Kim S; Kim SW; Kim YT
    Cancer Res Treat; 2020 Oct; 52(4):1211-1218. PubMed ID: 32599990
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic Value of Tumor Heterogeneity and SUVmax of Pretreatment 18F-FDG PET/CT for Salivary Gland Carcinoma With High-Risk Histology.
    Cheng NM; Hsieh CE; Liao CT; Ng SH; Wang HM; Fang YD; Chou WC; Lin CY; Yen TC
    Clin Nucl Med; 2019 May; 44(5):351-358. PubMed ID: 30932974
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment?
    Frezza AM; Beale T; Bomanji J; Jay A; Kalavrezos N; Dileo P; Whelan J; Strauss SJ
    BMC Cancer; 2014 Jan; 14():23. PubMed ID: 24422949
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
    Luo J; Zhou Z; Yang Z; Chen X; Cheng J; Shao Z; Guo X; Tuan J; Fu X; Yu X
    Medicine (Baltimore); 2016 Feb; 95(8):e2914. PubMed ID: 26937935
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET.
    Schulte M; Brecht-Krauss D; Werner M; Hartwig E; Sarkar MR; Keppler P; Kotzerke J; Guhlmann A; Delling G; Reske SN
    J Nucl Med; 1999 Oct; 40(10):1637-43. PubMed ID: 10520703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.